- Zacks Small Cap Research•8 days ago
Aethlon (AEMD) reported financial results for their first quarter 2017 and provided and operational update. Financial results were largely inline with our expectations although there was a notable positive variance in operating expenses, reflecting a combination of management's continued diligence on expense control as well as lower than anticipated spend on R&D - the latter which we attribute to slower trajectory to the U.S. feasibility study as compared to what we had been modeling. But the study is now 50% enrolled and management is still guiding for completion by current year-end. Revenue was just $5k in the quarter - inline with what we had expected, and entirely related to the Battelle subcontract. AEMD still has almost $400k under the DARPA contract yet to be billed, at least a portion of which we think could be booked in the current quarter (i.e.
- PR Newswire•15 days ago
SAN DIEGO, Aug. 11, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, today announced results for its fiscal ...
Aethlon Medical, Inc. (AEMD)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||5.28 x 100|
|Ask||5.30 x 100|
|Day's Range||5.26 - 5.46|
|52wk Range||4.02 - 9.09|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-6.91|
|Avg Vol (3m)||45,998|
|Dividend & Yield||N/A (N/A)|